Skip to main content
45°
Rain Shower
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kempharm Inc
(NQ:
KMPH
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
5.690 (8)
Ask (Size)
6.000 (20)
Prev. Close
5.810
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
33,932,639
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
February 22, 2023
From
KemPharm
Via
GlobeNewswire
KemPharm Announces Corporate Name Change to Zevra Therapeutics
February 22, 2023
From
KemPharm
Via
GlobeNewswire
Performance
More News
Read More
This Rare Disease Focused Stock Pipeline Is Underappreciated, Analyst Initiating Coverage Says
November 17, 2022
Via
Benzinga
KemPharm's Earnings: A Preview
November 08, 2022
Via
Benzinga
KemPharm's Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder
September 28, 2022
Via
Benzinga
Recap: KemPharm Q2 Earnings
August 11, 2022
Via
Benzinga
KemPharm Acquires Battered Orphazyme's Arimoclomol Program For $13M
May 16, 2022
Via
Benzinga
KemPharm's SDX Higher Dose Shows Potential Against Sleep Disorders
March 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022
Via
Benzinga
US Stocks Turn Lower; Nasdaq Drops Over 100 Points
September 15, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
September 15, 2022
Via
Benzinga
Apple To $220? Here Are 5 Other Price Target Changes For Wednesday
August 17, 2022
Via
Benzinga
Recap: KemPharm Q1 Earnings
May 12, 2022
Via
Benzinga
Earnings Preview For KemPharm
May 11, 2022
Via
Benzinga
The Technology Helping Existing FDA-Approved Drugs Target More Effectively
May 03, 2022
Via
Benzinga
Benzinga Announces This Week's All Access Guests
April 28, 2022
Via
Benzinga
26 Stocks Moving in Monday's Pre-Market Session
April 25, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
March 31, 2022
Via
Benzinga
Earnings Scheduled For March 30, 2022
March 30, 2022
Via
Benzinga
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
January 20, 2022
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Via
Benzinga
38 Stocks Moving In Monday's Mid-Day Session
December 20, 2021
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
February 16, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
Via
Benzinga
65 Biggest Movers From Yesterday
December 21, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
